Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xuezhiling tablets
- Development stage
- Unknown
- Lead developer
- Zhejiang Tianyitang Pharmaceutical
- Administration
- Oral
01
Overview
xuezhiling tablets (also known as Xuezhiling Pian) is a traditional Chinese medicine (TCM) formulation developed and manufactured by Zhejiang Tianyitang Pharmaceutical. It is composed of four main herbal ingredients: *Alisma plantago-aquatica* (Zexie), *Cassia obtusifolia* (Juemingzi), *Crataegus pinnatifida* (Shanzha), and *Polygonum multiflorum* (Zhiheshouwu). The formulation is approved in China for the treatment of hyperlipidemia, particularly for patients presenting with phlegm-dampness obstruction. It functions by resolving turbidity, lowering blood lipid levels, and promoting bowel movements.
- Other names
- Xuezhiling PianXuezhiling tablets血脂灵片
Beyond the preview
Go deeper on xuezhiling tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xuezhiling tablets.